Petri Dishes

Recent News

August 2022

August 2022 aTen Therapeutics awarded £282k Innovate UK grant to develop new breast cancer treatment.

March 2020

aTen Therapeutics relocates to new offices at 1 Lochrin Square, Fountainbridge, Edinburgh EH3 9QA.

August 2019

Ian Abercrombie appointed Chief Executive Officer at aTen Therapeutics.


aTen Therapeutics Ltd is a pre-clinical stage biotechnology company founded by Professor Christopher Wood, winner of the Lifetime Achievement Award at Scotland’s Annual Life Sciences Awards 2022.

Our management team has extensive experience within the biopharmaceutical industry, and a wealth of knowledge in building biotechnology companies. Past successes include the formation and subsequent growth of Bioenvision Inc. into a NASDAQ National listed, global biopharmaceutical company, acquired by Genzyme Corporation.

This experienced team is now applying its expertise to the growth of aTen Therapeutics and the development of therapeutic antibodies to the angiotensin-II type I receptor (AT1R) to treat cancers and other diseases.

A subsidiary of OncoBioPharm Ltd, aTen Therapeutics was recently awarded a substantial Innovate UK grant to accelerate the development of our lead candidate, ATN-E11.

© aTen Therapeutics 2022. All rights reserved